Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase IV | Natural history/Epidemiology | Temporarily closed | Any age | Pharmaceutical / Industry | 15246 NX0913IN, NCT01353794 |
Summary
The objective of this Non-Interventional study is to evaluate the effectiveness & safety of Nexavar in advanced Renal Cell Carcinoma (RCC) patients under daily-life treatment conditions based on age of the patient (older (age >70 years) and younger patients (age <70 years). Specifically investigated are the tumor status, duration of Nexavar ® treatment (number of cycles) and incidence of Hand foot Skin Reaction.
Eligibility Criteria
Inclusion Criteria:
- Patients with diagnosis of advanced Renal Cell Carcinoma (RCC) and decision taken by the investigator to prescribe Sorafenib
Exclusion Criteria:
- Exclusion criteria must be read in conjunction with the local product information.
Trial Lead Organizations/Sponsors
Bayer Corporation
| Bayer Study Director |  | Study Director |
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01353794
Information obtained from ClinicalTrials.gov on April 21, 2013
Back to Top
